This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Improving Treatment Approaches for Rectal Cancer

List of authors.
  • Hanna K. Sanoff, M.D., M.P.H.

The cure rate for nonmetastatic rectal cancer has been improving for decades. Treatment for stage II and III rectal adenocarcinomas now routinely includes surgery, radiation therapy, and chemotherapy. The results of recent phase 3 trials have led to an increase in the intensity of treatment to include multiagent chemotherapy in addition to radiation therapy before proctectomy is performed; such treatment has resulted in a 3-year disease-free survival rate as high as 77%.1,2 Unfortunately, this treatment approach is grueling and can cause substantial long-term sequelae, including neuropathy, infertility, and bowel and sexual dysfunction. However, this more aggressive preoperative treatment also opens . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

This editorial was published on June 5, 2022, at NEJM.org.

Author Affiliations

From the Division of Oncology and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.